Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence.

Clin Transl Oncol · 2021 · PMC8084841 · PMID 33206333

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significancep = 0.09so close (0.05 < p ≤ 0.1)

Edoxaban also showed reduced thrombosis recurrence, but the difference did not reach statistical significance (7.9 vs. 11.3%, HR 0.71, p = 0.09); a statistically significantly increased incidence of major bleeding was found with edoxaban (6.9 vs. 4%, HR 1.77, p = 0.04) compared to LMWH, which was attributable to a greater number of gastrointestinal (GI) bleeding events with edoxaban.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.